ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Trial Profile

ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Completed
Phase of Trial: Phase I

Latest Information Update: 15 Nov 2016

At a glance

  • Drugs Filanesib (Primary) ; Filanesib (Primary) ; Bortezomib; Bortezomib; Dexamethasone
  • Indications Multiple myeloma; Plasma cell leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Array BioPharma
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 15 Nov 2016 Results published in the Cancer
    • 19 Jul 2016 Results published in the Cancer (2016).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top